Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01609179 · ClinicalTrials.gov registry record · NA
IPI-926 Extension Protocol for Continuation of Treatment With IPI-926
A NA study, sponsored by Infinity Pharmaceuticals.
- Completed
- Registry status
- NA
- Development phase
- 9
- Enrollment target
NCT01609179: Completed NA study, sponsored by Infinity Pharmaceuticals.
NCT01609179 is a NA study that has completed, run by Infinity Pharmaceuticals. The registered enrollment target is 9 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01609179, a NA study, has completed, sponsored by Infinity Pharmaceuticals.
- COMPLETED
- Registry status
- NA
- Development phase
- 9 participants
- Enrollment target
Study Summary
A treatment protocol that enables patients to have continued access to IPI-926.
Primary Outcome
Monitoring of AEs, including SAEs as well as review of laboratory sample test data to assess safety and tolerability of IPI-926
Interventions
- DRUG IPI-926
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2012-03 |
| Est. Completion | 2012-11 |
| Phase | NA |
What the finished NCT01609179 record still lists
NCT01609179 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which IPI-926 is the first listed.
NCT01609179 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01609179 about?
NCT01609179 is a clinical study titled "IPI-926 Extension Protocol for Continuation of Treatment With IPI-926". A treatment protocol that enables patients to have continued access to IPI-926.
What is the current status of trial NCT01609179?
This trial is currently completed. It is a NA study. The enrollment target is 9 participants. The study started on 2012-03. Estimated completion is 2012-11.
What interventions are being tested in trial NCT01609179?
The interventions under investigation include: IPI-926 (DRUG).
Who is sponsoring clinical trial NCT01609179?
This trial is sponsored by Infinity Pharmaceuticals, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01609179's enrollment target sits among peer trials
9 1975th of 2000 higher than 25 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia